{
    "clinical_study": {
        "@rank": "18146", 
        "arm_group": [
            {
                "arm_group_label": "Alpha-1 HC 100 mg", 
                "arm_group_type": "Experimental", 
                "description": "100 mg of aerosolized Alpha-1 HC inhaled daily via nebulizer for 3 weeks."
            }, 
            {
                "arm_group_label": "Alpha-1 HC 200 mg", 
                "arm_group_type": "Experimental", 
                "description": "200 mg of aerosolized Alpha-1 HC inhaled daily via nebulizer for 3 weeks."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo inhaled daily via nebulizer for 3 weeks. Placebo (phosphate buffer saline with polysorbate) is composed of the same elements listed for Alpha-1 HC, minus Alpha-1 HC. Polysorbate 80 at 0.01% (weight/volume) is added to mimic the foaming properties of Alpha-1 HC."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, double-blind, placebo-controlled, dose escalation study to assess the\n      safety and tolerability of 100 mg and 200 mg of inhaled Alpha-1 HC administered once a day\n      for three weeks in subjects aged 18 years and older with cystic fibrosis (CF).  The\n      treatment duration in this study is intended to provide multi-dose safety information prior\n      to proceeding to longer durations of exposure."
        }, 
        "brief_title": "Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Cystic Fibrosis", 
        "condition_browse": {
            "mesh_term": [
                "Alpha 1-Antitrypsin Deficiency", 
                "Cystic Fibrosis", 
                "Fibrosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Documentation of CF diagnosis\n\n          -  Have a pre-bronchodilator FEV1 \u2265 40% of predicted at Visit 1 and have a Visit 2\n             pre-investigational product FEV1 that is \u2265 40% of predicted and within \u00b1 15% of the\n             Visit 1 result.\n\n          -  Deemed by the Investigator to be a suitable candidate for serial  collection of\n             expectorated sputum.\n\n        Exclusion Criteria:\n\n          -  Had a pulmonary exacerbation during the 4 weeks before screening (Visit 1) which\n             required the initiation of new antibiotic treatment\n\n          -  Have a pulmonary exacerbation during the screening period (between Visit 1 and Visit\n             2) which requires the initiation of new antibiotic treatment\n\n          -  FEV1 < 0.59 liters at the screening visit\n\n          -  Respiratory insufficiency with continuous supplemental oxygen therapy, or carbon\n             dioxide retention\n\n          -  Elevated aspartate transaminase (AST) or alanine aminotransferase (ALT) that is >/= 3\n             times the upper limit of normal for age and gender\n\n          -  Smoking during the past 6 months\n\n          -  Lung surgery during the past 2 years\n\n          -  Positive culture for Burkholderia cepacia or mycobacterium during the past two years.\n\n          -  Active allergic bronchopulmonary aspergillosis\n\n          -  Pre-treatment sputum collection at Visit 1 or Visit 2 (Randomization) characterized\n             by problems such as inadequate sputum volume or quality.\n\n          -  Known selective Immunoglobulin A (IgA) deficiency with known antibody against IgA\n             (anti-IgA antibody).\n\n          -  History of anaphylaxis or severe systemic response to any plasma-derived\n             alpha1-proteinase inhibitor preparation or other blood product(s), or to\n             polysorbates.\n\n          -  Use of chronic, high dose ibuprofen therapy within 3 weeks of screening and at\n             anytime during the study.\n\n          -  Chronic maintenance therapy with systemic antibiotics within 3 weeks of screening and\n             through last dose of investigational product.\n\n          -  Use of leukotriene synthesis inhibitor (zileuton) or leukotriene receptor antagonists\n             (montelukast, zafirlukast) within 3 weeks of screening and at anytime during the\n             study.\n\n          -  Use of roflumilast within 3 weeks of screening and at anytime during the study.\n\n          -  Initiation of a new chronic medication or dosage change of a chronic medication for\n             treatment of cystic fibrosis (example:  Kalydeco\u2122 [ivacaftor]) within 3 weeks of\n             screening (Visit 1)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "41", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01684410", 
            "org_study_id": "T6005-201"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Alpha-1 HC 100 mg", 
                    "Alpha-1 HC 200 mg"
                ], 
                "description": "Alpha-1 HC is a sterile, liquid preparation of purified alpha1-proteinase inhibitor prepared from pooled human plasma.", 
                "intervention_name": "Alpha-1 HC", 
                "intervention_type": "Biological", 
                "other_name": [
                    "Alpha1-proteinase inhibitor", 
                    "alpha1-antitrypsin"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Alpha 1-Antitrypsin", 
                "Protein C Inhibitor", 
                "Protease Inhibitors"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Cystic Fibrosis", 
            "Alpha1-proteinase inhibitor", 
            "Alpha1-antitrypsin"
        ], 
        "lastchanged_date": "November 26, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35233"
                    }, 
                    "name": "The University of Alabama at Birmingham"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80206"
                    }, 
                    "name": "National Jewish Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Children's Hospital Boston"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599"
                    }, 
                    "name": "UNC at Chapel Hill"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44106"
                    }, 
                    "name": "Rainbow Babies and Children's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29425"
                    }, 
                    "name": "Medical University of South Carolina"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Three Week Dose Escalation, Randomized, Double-Blind, Placebo-Controlled Trial, to Assess the Safety and Tolerability of 100 mg or 200 mg of Inhaled Alpha-1 HC, Once a Day in Subjects With Cystic Fibrosis.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "FEV1 conducted before and after inhalation of the investigational product.", 
                "measure": "Forced Expiratory Volume in 1 second (FEV1)", 
                "safety_issue": "Yes", 
                "time_frame": "3 weeks"
            }, 
            {
                "description": "The number of subjects with adverse events.", 
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "3 weeks"
            }, 
            {
                "description": "FVC conducted before and after inhalation of the investigational product.", 
                "measure": "Forced Vital Capacity (FVC)", 
                "safety_issue": "Yes", 
                "time_frame": "3 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01684410"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Grifols Therapeutics Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Grifols Therapeutics Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}